Biomarkers and Personalized Medicine
12.3K views | +0 today
Follow
Biomarkers and Personalized Medicine
Sharing relevant articles on advancements in personalized medicine
Curated by Brian Shields
Your new post is loading...
Your new post is loading...
Scooped by Brian Shields
Scoop.it!

Low Mmp 9 and VEGF levels predict good oncologic outcome in mid and low rectal cancer patients with neoadjuvant chemoradiation

Low Mmp 9 and VEGF levels predict good oncologic outcome in mid and low rectal cancer patients with neoadjuvant chemoradiation - up-to-the-minute news and headlines.
more...
No comment yet.
Scooped by Brian Shields
Scoop.it!

VEGF pathway-targeted therapy for advanced renal cell carcinoma: A meta-analysis of randomized controlled trials

VEGF pathway-targeted therapy for advanced renal cell carcinoma: A meta-analysis of randomized controlled trials | Biomarkers and Personalized Medicine | Scoop.it

"Immunotherapy which has been in practice for more than 20 years proves effective for the treatment of metastatic renal cell carcinoma (mRCC). Anti-angiogenesis-targeted therapy has recently been identified as a promising therapeutic strategy for mRCC. This study was aimed to evaluate the effectiveness of vascular endothelial growth factor (VEGF) pathway-targeted therapy for mRCC by comparing its effectiveness with that of immunotherapy. The electronic databases were searched..."

more...
No comment yet.
Scooped by Brian Shields
Scoop.it!

AVEO's Triple VEGF Receptor Inhibitor Tivozanib in Combination ...

AVEO's Triple VEGF Receptor Inhibitor Tivozanib in Combination with mTOR Inhibitor Demonstrates Anti-tumor Activity and Tolerability in Advanced Kidney Cancer; Preliminary Results Presented at AACR-NCI-EORTC ...
more...
No comment yet.
Scooped by Brian Shields
Scoop.it!

Novel Agents and Approaches for Advanced Renal Cell Carcinoma

Exceprt from Abstract: "RESULTS:

A total of 11 novel targeted agents, including next generation tyrosine kinase inhibitors, and inhibitors of vascular endothelial growth factor ligand binding, Akt and endothelial cell proliferation, and 3 novel immunomodulatory agents, are under evaluation for renal cell carcinoma. In addition to ongoing phase II/III trials of emerging agents, head-to-head, crossover and combination trials of approved targeted agents are under way."

more...
No comment yet.
Scooped by Brian Shields
Scoop.it!

Access : Treatment of everolimus-resistant metastatic renal cell carcinoma with VEGF-targeted therapies : British Journal of Cancer

"Background:

Treatment of everolimus-resistant disease remains largely undefined in metastatic renal cell carcinoma (mRCC). We report on 40 patients (pts) who receive systemic treatment after failure of everolimus.

Patients and methods:

Forty pts received sunitinib (n=19), sorafenib (n=8), dovitinib (n=10) or bevacizumab/interferon (n=3) after failure of everolimus. Median progression-free survival (PFS), overall survival (OS) and best tumour response (according to Response Evaluation Criteria In Solid Tumors) were analysed retrospectively. Kaplan–Meier, log-rank test and Cox regression analyses were used to estimate or predict OS and PFS.

Results:

Treatment of everolimus-resistant disease was associated with a PFS of 5.5 months. (range 0.4–22.3) and an objective partial remission (PR) in 4 pts (10%) and stable disease (SD) in 22 pts (55%). In univariate analyses, first-line treatment with sorafenib was the only variable to correlate with a prolonged PFS of treatment in everolimus-resistant disease (P=0.036). However, its significance as a predictive marker for subsequent therapy could not be verified in multivariate analyses."

more...
No comment yet.